Total raised
—
Stage
Pre-Funding
Founded
2020
Headcount
2
HQ
Tel Aviv-Yafo
Sector
Health Tech & Life Sciences
About
OBCTCD24 is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-delivered, CD24-based therapeutics a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need.
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is the primary focus of OBCTCD24?
- OBCTCD24 is a clinical-stage biopharmaceutical company focused on developing exosome-delivered, CD24-based therapeutics.
- When was OBCTCD24 founded?
- OBCTCD24 was founded in August 2020.
- What is the current operational status of OBCTCD24?
- OBCTCD24 is currently inactive, having ceased operations in December 2021.
- Where is OBCTCD24 headquartered?
- OBCTCD24 is headquartered in Tel Aviv-Yafo, Israel.
- What is OBCTCD24's current funding stage?
- OBCTCD24 is in the Pre-Funding stage.
- How many employees did OBCTCD24 have?
- OBCTCD24 had between 1 and 10 employees, with an exact count of 2.
- What is the primary sector of OBCTCD24?
- The primary sector of OBCTCD24 is Health Tech & Life Sciences.
- What was a notable news event related to OBCTCD24 in April 2021?
- In April 2021, news reported that an Israeli hospital claimed to have found a cure for COVID-19, which was associated with OBCTCD24.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2B
Tags
autoimmune-diseasespharmaceuticalshealthcare-providersdrug-developmentbiopharmaceuticalrespiratorytherapeuticsbiotechnologyinhalation